SEC Form 4 · accession 0001017491-16-000130
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Morton
Officer — SVP, Chief Business Officer
Period of report
Apr 1, 2016
Accepted (ET)
Apr 5, 2016 · 8:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.57 | Apr 1, 2016 | A | 165,000 | A | — | Mar 29, 2026 | Common Stock | 165,000 | 165,000 | D |
Explanation of responses
- F1This option shall vest with respect to one-fourth of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years so the option will be fully vested as of 4/1/2020, subject to the Reporting Person's continued employment or service to the Issuer through such date.